Striatal dopamine deficiency in Parkinson's disease: role of aging.
about
The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegenerationAging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's diseaseN-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line DataThe Wld(S) mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo.Relationship of striatal dopamine synthesis capacity to age and cognition.Clinical progression in Parkinson disease and the neurobiology of axons.Age-related changes in dopamine signaling in Nurr1 deficient mice as a model of Parkinson's diseaseTranscription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons.Ageing and the nigrostriatal dopaminergic system.Intracellular signalling pathways in dopamine cell death and axonal degeneration.Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity.Axon degeneration in Parkinson's diseaseNeurodegeneration and neuroprotection in Parkinson disease.Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment.Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.Redox imbalance in Parkinson's disease.Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease.Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.Functional connectivity of substantia nigra and ventral tegmental area: maturation during adolescence and effects of ADHD.Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug?Oral biomarkers in exercise-induced neuroplasticity in Parkinson's disease.Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease.In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.The catecholamine transporter of adrenal medulla chromaffin granules.Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies.Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.Striatal kinetic modeling of FDOPA with a cerebellar-derived constraint on the distribution of volume of 30MFD: a PET investigation using non-human primates.Responsiveness of striatal dopamine release in awake animals after chronic 1-methyl-4-phenylpyridinium ion-induced lesions of the substantia nigra.The metabolic topography of normal aging.Client perception of therapeutic factors in group psychotherapy and growth groups: an empirically-based hierarchical model.New concepts in Parkinson's disease.Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography.7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study.On the rate of decarboxylation of dopa to dopamine in living mammalian brain.Effects of large neutral amino acid concentrations on 6-[F-18]Fluoro-L-DOPA kinetics.Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate.The effect of age on motor deficits and cerebral glucose metabolism of Parkinson's disease.
P2860
Q24322927-94FCBF47-E5B7-441D-B343-8B4D9D7A2980Q28324372-54CC9C00-85AE-4AD4-A6AA-FD2E1B7EE0E1Q30000089-FBABF12A-F055-4E2A-908F-B605CE6FD71EQ33841702-6884E51D-4F7E-4FAD-A9D0-CD9CCB6B5347Q33894630-69367A0E-DA7D-408D-AD8E-294F0837782BQ34052764-3D85D8E3-1CBC-4671-9078-1D4EF88D5FB1Q34181259-0720800A-7E65-464B-9381-EB9B9E192149Q34557895-35B4C0F5-4BBA-4DEE-884E-B423621F003FQ34627373-A579C9F4-654D-4D74-B800-062012502B6AQ34936423-DC8F2C83-7232-4698-AFC5-3D668710EFB4Q35807528-883270B2-EBCD-4AC4-BB61-A504DC142455Q35878214-404392DD-86B4-43D6-BAC6-2FC996163F48Q35923102-C19C6C17-B3A8-45AD-9F8A-E2CD474C2223Q36045259-07FA31AB-51FF-4F51-A23A-396A188ABB0FQ36101699-E3645DBB-B011-4C4D-8295-CDE2A0AEE8B9Q36236735-DF9C1A1A-6A39-4396-8D78-A75CDA967D28Q36899782-DECA066D-0C7B-4B46-BBE8-8530447942FBQ36947501-534C8ACD-555A-408C-901F-265C270D7EECQ37423949-7EB3EEB7-2937-4525-B2DC-EC688DB37D18Q37628349-2088AC61-E14A-4390-8778-3F89A7FE1DCEQ37715032-22A870AA-305C-4CFA-BB7B-37E4C3CECA6BQ37886152-4749D56C-521D-47D2-A040-DD899C4B6523Q38733922-34125188-A91E-4E4C-8D1E-5747144A2DD9Q39075710-C7C38288-DAF7-44DC-92A6-7C9DBF0C2D41Q39758264-2545DD55-9520-4275-8008-F269BE329046Q40642408-3DE863B7-2066-441D-B542-AA22B09780B5Q41589030-6DB68FFE-1022-4BA0-BC69-614ED4163B84Q41743797-C7D97CDF-2E23-4A9B-A8B5-8326D3EC7B29Q41749687-F8CBF699-83F9-48CC-9EEC-EE8D5C0A2A63Q42475696-404A9275-C366-4C5C-8BE7-ACBA1BD61461Q42629288-F972D62C-F4D2-4F13-8679-FBED8BA8FCD0Q43521319-09A1CD37-34F4-40C1-B97F-B7BCDCB42731Q44803598-D8BF4BE8-FF56-4B08-9FF3-4C3D04290A70Q46900351-EDCE524E-7378-4813-B2AD-B57C2F3798F0Q48271131-44CDFD36-00B7-4501-B52B-72CFC7DAE6F9Q48293950-9932642E-A2ED-4531-9327-45A4C5276587Q48455026-43E384ED-AE6B-42D2-B28E-54FE1F98D3E1Q48564407-FB154CBF-E926-420F-BB44-CEC451488AB7Q48764121-4BCEE49C-C2F9-4FC9-B912-A2EF18076018Q50267265-237D4B95-D06F-46CB-8E7B-F24C94CCABD0
P2860
Striatal dopamine deficiency in Parkinson's disease: role of aging.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Striatal dopamine deficiency in Parkinson's disease: role of aging.
@en
type
label
Striatal dopamine deficiency in Parkinson's disease: role of aging.
@en
prefLabel
Striatal dopamine deficiency in Parkinson's disease: role of aging.
@en
P2093
P2860
P356
P1433
P1476
Striatal dopamine deficiency in Parkinson's disease: role of aging.
@en
P2093
P2860
P304
P356
10.1002/ANA.410260409
P50
P577
1989-10-01T00:00:00Z